Glucagon-like-peptide 1 receptor agonist for metabolic dysfunction-associated steatotic liver disease: hype or hope?
作者信息
Wong Yu Jun, Goh George Boon-Bee
机构信息
Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore.
Duke-NUS Medical School, Singapore.
出版信息
Singapore Med J. 2025 Apr 1;66(4):173-174. doi: 10.4103/singaporemedj.SMJ-2025-051. Epub 2025 Apr 22.
Abstract
摘要
相似文献
1
Glucagon-like-peptide 1 receptor agonist for metabolic dysfunction-associated steatotic liver disease: hype or hope?用于代谢功能障碍相关脂肪性肝病的胰高血糖素样肽-1受体激动剂：炒作还是希望？
Singapore Med J. 2025 Apr 1;66(4):173-174. doi: 10.4103/singaporemedj.SMJ-2025-051. Epub 2025 Apr 22.
2
Treatment of rapid recurrence of severe steatosis with combined glucagon-like peptide-1 agonist and growth hormone therapy in a pediatric patient transplanted for metabolic dysfunction-associated steatohepatitis cirrhosis in the setting of hypopituitarism.在一名因代谢功能障碍相关脂肪性肝炎肝硬化合并垂体功能减退而接受移植的儿科患者中，联合使用胰高血糖素样肽-1激动剂和生长激素疗法治疗严重脂肪变性的快速复发。
Am J Transplant. 2025 May;25(5):1123-1126. doi: 10.1016/j.ajt.2025.01.002. Epub 2025 Jan 8.
3
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.GLP-1/胰高血糖素双重受体激动剂佩米度肽对代谢相关脂肪性肝病的影响：一项随机、双盲、安慰剂对照研究。
J Hepatol. 2025 Jan;82(1):7-17. doi: 10.1016/j.jhep.2024.07.006. Epub 2024 Jul 11.
4
Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.胰高血糖素样肽 1 激动剂可能是治疗代谢功能障碍相关脂肪性肝病的有效药物。
World J Gastroenterol. 2024 Aug 14;30(30):3541-3547. doi: 10.3748/wjg.v30.i30.3541.
5
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.胰高血糖素样肽 1、葡萄糖依赖性胰岛素促分泌多肽和胰高血糖素受体激动剂在代谢功能障碍相关脂肪性肝病中的作用：新肝病命名中的新型药物。
Int J Mol Sci. 2024 Mar 29;25(7):3832. doi: 10.3390/ijms25073832.
6
Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.胰高血糖素样肽-1 受体激动剂治疗代谢相关脂肪性肝病伴肝脂肪变的瞬时弹性成像变化：一项真实世界回顾性分析。
Metab Syndr Relat Disord. 2024 Oct;22(8):608-618. doi: 10.1089/met.2024.0115. Epub 2024 Jun 13.
7
Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.肠促胰岛素和胰高血糖素受体激动剂在代谢功能障碍相关脂肪性肝病中的作用：机遇与挑战
World J Hepatol. 2024 May 27;16(5):731-750. doi: 10.4254/wjh.v16.i5.731.
8
Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes.胰高血糖素样肽-1受体激动剂可改善代谢功能障碍相关脂肪性肝病的预后。
Sci Rep. 2025 Feb 10;15(1):4947. doi: 10.1038/s41598-025-89408-z.
9
Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy.肠道微生物群、胰高血糖素样肽受体激动剂与营养的相互作用：代谢功能障碍相关脂肪性肝病治疗的新前沿。
World J Gastroenterol. 2024 Nov 21;30(43):4682-4688. doi: 10.3748/wjg.v30.i43.4682.
10
Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective.胰高血糖素样肽-1受体激动剂在代谢功能障碍相关脂肪性肝病中的现状：临床视角
J Clin Transl Hepatol. 2025 Jan 28;13(1):47-61. doi: 10.14218/JCTH.2024.00271. Epub 2024 Nov 6.
本文引用的文献
1
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.亚太肝脏研究协会代谢功能障碍相关脂肪性肝病诊断和管理临床实践指南
Hepatol Int. 2025 Apr;19(2):261-301. doi: 10.1007/s12072-024-10774-3. Epub 2025 Feb 27.
2
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021.2010年至2021年代谢功能障碍相关脂肪性肝病的全球负担
JHEP Rep. 2024 Nov 14;7(3):101271. doi: 10.1016/j.jhepr.2024.101271. eCollection 2025 Mar.
3
Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.代谢功能障碍相关脂肪性肝炎中用于纤维化消退和MASH缓解的药物治疗比较：系统评价和网状Meta分析
Hepatology. 2025 Feb 4. doi: 10.1097/HEP.0000000000001254.
4
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.GLP-1 受体激动剂与代谢相关脂肪性肝病合并非酒精性脂肪性肝病患者发生肝硬化及相关并发症的风险
JAMA Intern Med. 2024 Nov 1;184(11):1314-1323. doi: 10.1001/jamainternmed.2024.4661.
5
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.替尔泊肽治疗代谢相关脂肪性肝炎伴肝纤维化
N Engl J Med. 2024 Jul 25;391(4):299-310. doi: 10.1056/NEJMoa2401943. Epub 2024 Jun 8.
6
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.MASH 和纤维化中苏沃杜肽的 2 期随机试验。
N Engl J Med. 2024 Jul 25;391(4):311-319. doi: 10.1056/NEJMoa2401755. Epub 2024 Jun 7.
7
Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes.GLP-1 受体激动剂与 2 型糖尿病患者肝癌发病率和肝功能失代偿的相关性。
Gastroenterology. 2024 Sep;167(4):689-703. doi: 10.1053/j.gastro.2024.04.029. Epub 2024 Apr 29.
8
Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial.利拉鲁肽对超重或肥胖成年人大腿肌肉脂肪和肌肉成分的影响：一项随机临床试验的结果。
J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):1072-1083. doi: 10.1002/jcsm.13445. Epub 2024 Apr 1.
9
Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH.用于治疗非酒精性脂肪性肝炎的甲状腺激素受体β选择性激动剂。
N Engl J Med. 2024 Feb 8;390(6):559-561. doi: 10.1056/NEJMe2314365.
10
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
Zotero 插件